1.Effect of Progesterone on COX-2 Expression and Proliferation of Prostate Stromal Cell.
Soo Ryun JUNG ; Sung Han KIM ; E Hwa CHOI ; Ji Eun PARK ; Eun Mi JEON ; Young Jin KANG ; Kwang Youn LEE ; Hyoung Chul CHOI
Yeungnam University Journal of Medicine 2006;23(1):62-70
BACKGROUND: Benign prostatic hyperplasia (BPH) is the most common benign tumor in older men; the etiology of this disease remains poorly understood. Testosterone and dihydrotestosterone (DHT) both act as androgen via a single androgen receptor. Testosterone is converted to DHT by 5alpha-reductase in prostatic stromal cells. Progesterone has been reported to inhibit DHT conversion; howevwe, its effect on prostatic stromal cells remains to be elucidated. MATERILAS AND METHODS: In this experiment, we investigated the effect of progesterone on androgen receptor expression induced by DHT. We also tested the effect of progesterone on cyclooxygenase-2 (COX-2) expression, as well as prostate stromal cell proliferation using the cell count kit-8. RESULTS: Progesterone did not cause an increase of prostate stromal cell proliferation. The mRNA expression of the androgen receptor and COX-2 were not changed by progesterone; the expressions of androgen receptor and COX-2 proteins were decreased by progesterone in prostate stromal cells. CONCLUSION: These results suggest that in prostate stromal cells, progesterone decreases androgen receptor protein expression, which results in decrement of COX-2 protein expression. This effect might be mediated by post-transcriptional regulation.
Cell Count
;
Cyclooxygenase 2
;
Dihydrotestosterone
;
Humans
;
Male
;
Progesterone*
;
Prostate*
;
Prostatic Hyperplasia
;
Receptors, Androgen
;
RNA, Messenger
;
Stromal Cells*
;
Testosterone
2.Clinical characteristics and perinatal outcome of fetal hydrops.
Wonkyung YEOM ; E Sun PAIK ; Jung Joo AN ; Soo Young OH ; Suk Joo CHOI ; Cheong Rae ROH ; Jong Hwa KIM
Obstetrics & Gynecology Science 2015;58(2):90-97
OBJECTIVE: To investigate the clinical characteristics of fetal hydrops and to find the antenatal ultrasound findings predictive of adverse perinatal outcome. METHODS: This is a retrospective study of 42 women with fetal hydrops who delivered in a tertiary-referral center from 2005 to 2013. Fetal hydrops was defined as the presence of fluid collection in > or =2 body cavities: ascites, pleural effusion, pericardial effusion, and skin edema. Predictor variables recorded included: maternal characteristics, gestational age at diagnosis, ultrasound findings, and identifiable causes. Primary outcome variables analyzed were fetal death and neonatal death. RESULTS: The mean gestational age at diagnosis was 29.3+/-5.4 weeks (range, 18 to 39 weeks). The most common identifiable causes were cardiac abnormality (10), followed by syndrome (4), aneuploidy (3), congenital infection (3), twin-to-twin transfusion syndrome (3), non-cardiac anormaly (2), chorioangioma (2), inborn errors of metabolism (1), and immune hydrops by anti-E antibody isoimmunization (1). Thirteen cases had no definite identifiable causes. Three women elected termination of pregnancy. Fetal death occurred in 4 cases. Among the 35 live-born babies, only 16 survived (54.0% neonatal mortality rate). Fetal death and neonatal mortality rate was not significantly associated with Doppler velocimetry indices or location of fluid collection, but increasing numbers of fluid collection site was significantly associated with a higher risk of neonatal death. CONCLUSION: The incidence of fetal hydrops in our retrospective study was 24.4 per 10,000 deliveries and the perinatal mortality rate was 61.9% (26/42). The number of fluid collection sites was the significant antenatal risk factor to predict neonatal death.
Aneuploidy
;
Ascites
;
Diagnosis
;
Edema
;
Female
;
Fetal Death
;
Fetofetal Transfusion
;
Gestational Age
;
Hemangioma
;
Humans
;
Hydrops Fetalis*
;
Incidence
;
Infant
;
Infant Mortality
;
Metabolism, Inborn Errors
;
Pericardial Effusion
;
Perinatal Mortality
;
Pleural Effusion
;
Pregnancy
;
Retrospective Studies
;
Rheology
;
Risk Factors
;
Skin
;
Ultrasonography
3.Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020
Mee Joo KANG ; Kyu-Won JUNG ; So Hyun BANG ; Seo Hyun CHOI ; Eun Hye PARK ; E Hwa YUN ; Hye-Jin KIM ; Hyun-Joo KONG ; Jeong-Soo IM ; Hong Gwan SEO ;
Cancer Research and Treatment 2023;55(2):385-399
Purpose:
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.
Materials and Methods:
Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.
Results:
The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.
Conclusion
In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future.
4.Regional disparities in major cancer incidence in Korea, 1999-2018
Eun Hye PARK ; Mee Joo KANG ; Kyu-Won JUNG ; Eun Hye PARK ; E Hwa YUN ; Hye-Jin KIM ; Hyun-Joo KONG ; Chang Kyun CHOI ; Jeong-Soo IM ; Hong Gwan SEO ;
Epidemiology and Health 2023;45(1):e2023089-
OBJECTIVES:
This study investigated regional disparities in the incidence of 8 major cancers at the municipal level in Korea during 1999-2018 and evaluated the presence or absence of hot spots of cancer clusters during 2014-2018.
METHODS:
The Korea National Cancer Incidence Database was used. Age-standardized incidence rates were calculated by gender and region at the municipal level for 4 periods of 5 years and 8 cancer types. Regional disparities were calculated as both absolute and relative measures. The possibility of clusters was examined using global Moran’s I with a spatial weight matrix based on adjacency or distance.
RESULTS:
Regional disparities varied depending on cancer type and gender during the 20-year study period. For men, the regional disparities of stomach, colon and rectum, lung, and liver cancer declined, and those of thyroid and prostate cancer recently decreased, despite an overall increasing incidence. For women, regional disparities in stomach, colon and rectum, lung, liver, and cervical cancer declined, that of thyroid cancer recently decreased, despite an overall increasing incidence, and that of breast cancer steadily increased. In 2014-2018, breast cancer (I, 0.61; 95% confidence interval [CI], 0.53 to 0.70) showed a high probability of cancer clusters in women, and liver cancer (I, 0.48; 95% CI, 0.40 to 0.56) showed a high probability of cancer clusters in men.
CONCLUSIONS
Disparities in cancer incidence that were not seen at the national level were discovered at the municipal level. These results could provide important directions for planning and implementing local cancer policies.
5.Clinical Characteristics of ESRD Patients with Severe Hyperparathyroidism Who Undertook Surgical Parathyroidectomy.
Seung Hyeok HAN ; Sang Cheol LEE ; E Hwa KANG ; Young Suk GOO ; Hyung Chun PARK ; Hyun Jeong ROH ; Hyun Jin NOH ; Soo Young YOON ; Do Sik YUN ; So Rye CHOI ; Shin Wook KANG ; Kyu Hun CHOI ; Ho Yung LEE ; Dae Suk HAN ; Jin Hak SEO ; Wung Yoon JEONG ; Jeong Soo PARK
Korean Journal of Nephrology 2002;21(1):108-116
BACKGROUND: Medical treatments such as restriction of phosphate, phosphate binder use, and active vitamine D therapy have been widely used for hyperparathyroidism in ESRD patients, and surgical parathyroidectomy should be considered in patients with uncontrolled hyperparathyroidism. METHODS: A retrospective study was performed in 24 ESRD patients with severe and uncontrolled hyperparathyroidism despite of medical treatment who undertook surgical parathyroidectomy in Severance hospital from 1990 to 1999. RESULTS: Sixteen patients had total parathyroidectomy with immediate autotransplant, 7 patients had subtotal parathyroidectomy and only 1 patient had minimally invasive parathyroidectomy. An excellent short-term control of hyperparathyroidism was achieved in all patients after parathyroidectomy. Preoperative bone and joint pain improved in 16 of 19 patients. Muscle weakness and pain improved in 11 of 17 patiens, malaise improved in 8 of 10 patients and pruritus improved in 10 of 13 patients. In addition, clinical laboratory finding improved after parathyroidectomy. No clinical differences were seen between 16 patients who undertook total parathyroidectomy with immediate autotransplant and 7 patients who undertook subtotal parathyroidectomy. Recurrence of hyperparathyroidism ocurred in 5 of 24 patients with 4 nodular hyperplasia and 1 diffuse hyperplasia in pathologic finding. The less degree of attenuated response of intact PTH levels immediately after operation was observed in 5 recurrent cases. CONCLUSION: Good results were obtained after parathyroidectomy. We believe that histologic subtype and the attenuated response of intact PTH after surgical parathyroidectomy could be possible predictors of the recurrent hyperparathyroidism.
Arthralgia
;
Autografts
;
Humans
;
Hyperparathyroidism*
;
Hyperparathyroidism, Secondary
;
Hyperplasia
;
Kidney Failure, Chronic*
;
Muscle Weakness
;
Parathyroidectomy*
;
Pruritus
;
Recurrence
;
Retrospective Studies
;
Vitamins
6.Inappropriateness of Quinolone in Scrub Typhus Treatment Due to gyrA Mutation in Orientia tsutsugamushi Boryong Strain.
Hee Chang JANG ; Su Mi CHOI ; Mi Ok JANG ; Joon Hwan AHN ; Uh Jin KIM ; Seung Ji KANG ; Jong Hee SHIN ; Hyon E CHOY ; Sook In JUNG ; Kyung Hwa PARK
Journal of Korean Medical Science 2013;28(5):667-671
The use of quinolone for treatment of rickettsial diseases remains controversial. Recent clinical studies suggest that quinolone is not as effective as others in patients with rickettsial diseases including scrub typhus, although the mechanism is not well understood. In this study, we evaluated the mutation in gyrA associated with quinolone resistance. We prospectively enrolled scrub typhus patients, collected blood samples and clinical data from October, 2010 to November, 2011. Among the 21 patients enrolled, one initially received ciprofloxacin for 3 days but was switched to doxycycline due to clinical deterioration. We obtained the gyrA gene of Orientia tsutsugamushi from 21 samples (20 Boryong strain, 1 Kato strain) and sequenced the quinolone resistance-determining region. All of 21 samples had the Ser83Leu mutation in the gyrA gene, which is known to be associated with quinolone resistance. This suggests that quinolones may be avoided for the treatment of serious scrub typhus.
Aged
;
Aged, 80 and over
;
Amino Acid Sequence
;
Anti-Bacterial Agents/*therapeutic use
;
Bacterial Proteins/*genetics
;
Ciprofloxacin/*therapeutic use
;
DNA Gyrase/*genetics
;
Doxycycline/therapeutic use
;
Drug Resistance, Bacterial
;
Female
;
Genotype
;
Humans
;
Male
;
Middle Aged
;
Molecular Sequence Data
;
Mutation
;
Orientia tsutsugamushi/classification/enzymology/*genetics
;
Phylogeny
;
Prospective Studies
;
Scrub Typhus/*drug therapy
;
Sequence Alignment
;
Sequence Analysis, DNA